COMMENTARY

55  The Many Faces of Guillain-Barré Syndrome
    E. Steve Roach

ARTICLES

57  Pediatric Solid Tumors of Infancy: An Overview
    Wendy Allen-Rhoades, Sarah B. Whittle, Nino Rainusso

68  Recognizing and Referring Children with Posttraumatic Stress Disorder: Guidelines for Pediatric Providers
    Helen W. Wilson, Shashank V. Joshi

78  Kawasaki Disease
    Mary Beth F. Son, Jane W. Newburger

INDEX OF SUSPICION

91  Case 1: Vomiting and Ventricular Arrhythmia in a 2-year-old Girl
    Benjamin H. Gern, Amit Mehta, Amy N. McCammond, Kathryn W. Holmes, Judith A. Guzman-Cottrill

93  Case 2: Headache and Behavior Changes in an 11-year-old Boy
    David Mills, Lindsey C. Yock, Erin King

94  Case 3: Progressive Leg Pain and Weakness in a 16-year-old Boy
    Amanda Begley, Alicia Briggs, Christopher Williams

95  Case 4: Poor Feeding and Lethargy in a 32-day-old Infant
    Erin R. Peebles, Tamara A. VanHoorens, Anna C. Gunz, Marina I. Salvadori

96  Case 5: Prolonged Fever in a 5-year-old Girl of Myanmese Descent
    Fernando Bula-Rudas, Mobeen Rathore

98  Case 6: An Infant Presenting with Hematuria and Pallor
    Lauren C. Riney, Jennifer D. Treasure, Charles D. Varnell Jr, Holly Depinet

IN BRIEFS

100   Cyclic Vomiting Syndrome
      Michael S. Foreman, Tammy Camp

102   Human Trafficking
      Amy C. Brown, Christine E. Barron

104   Trisomies
      Paul A. Levy, Robert Marion

ONLINE

e5   Visual Diagnosis: A Rapidly Progressive Soft Tissue Shoulder Mass in a 3-month-old Infant
      James C. League-Pascual, Kip R. Hartman

Answer Key appears on page 106.
Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of offers 36 CME articles per year. A maximum of one –Nahed Abdel-Haq, MD –Basim Asmar, MD –Lalitha Sivaswamy, MD –Laura Ibsen, MD –Sydney Rice, MD, MSc

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy of a new drug potentially of use in irritable bowel syndrome.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose to the AAP and subsequently to learners that the individual either has no relevant financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. Commercial interest is defined as any entity producing, marketing, reselling or distributing health-care goods or services consumed by, or used on, patients.

Each of the editorial board members, reviewers, question writers, and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of presents 36 CME articles per year. A maximum of one –Nahed Abdel-Haq, MD –Basim Asmar, MD –Lalitha Sivaswamy, MD –Laura Ibsen, MD –Sydney Rice, MD, MSc

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy of a new drug potentially of use in irritable bowel syndrome.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of offers 36 CME articles per year. A maximum of one –Nahed Abdel-Haq, MD –Basim Asmar, MD –Lalitha Sivaswamy, MD –Laura Ibsen, MD –Sydney Rice, MD, MSc

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy of a new drug potentially of use in irritable bowel syndrome.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of presents 36 CME articles per year. A maximum of one –Nahed Abdel-Haq, MD –Basim Asmar, MD –Lalitha Sivaswamy, MD –Laura Ibsen, MD –Sydney Rice, MD, MSc

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy of a new drug potentially of use in irritable bowel syndrome.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of presents 36 CME articles per year. A maximum of one –Nahed Abdel-Haq, MD –Basim Asmar, MD –Lalitha Sivaswamy, MD –Laura Ibsen, MD –Sydney Rice, MD, MSc

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy of a new drug potentially of use in irritable bowel syndrome.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Philip Fischer, MD, disclosed he has received honoraria from Relias Learning (AHC Media).
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of a new drug potentially of use in irritable bowel syndrome.
- E. Steve Roach, MD, receives an honorarium from Elsevier for serving as editor of presents 36 CME articles per year. A maximum of one –Nahed Abdel-Haq, MD –Basim Asmar, MD –Lalitha Sivaswamy, MD –Laura Ibsen, MD –Sydney Rice, MD, MSc

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Miriam Weinstein, MD, is a paid consultant participating on the ad boards: for a new topical eczema product for Pfizer Inc.; and for a systemic eczema therapy of a new drug potentially of use in irritable bowel syndrome.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits/writes/reviews may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.
Updated Information & Services

including high resolution figures, can be found at:
http://pedsinreview.aappublications.org/content/39/2

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints

Information about ordering reprints can be found online:
http://classic.pedsinreview.aappublications.org/content/reprints
The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pedsinreview.aappublications.org/content/39/2